Vertex completes telaprevir NDA

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) completed submission of a rolling NDA to FDA for telaprevir to treat HCV infection. The company requested Priority Review for the small molecule HCV NS3/4A pr...